Michigan House Bill HB4252

Michigan 2025-2026 Regular Session

• Introduced: 3/18/25
• Refer: 3/18/25

Caption

House Bill 4252 of 2025

Summary

House Bill 4252 would amend Michigan’s Public Health Code to require that, when a manufacturer packages or repackages a non-controlled drug in a blister pack for distribution in the state, the blister pack must display at least the drug’s generic name. If the blister pack has perforated blister cells, the name must appear on each cell; if it does not, the generic name must appear on the backing of the pack. The bill applies only to drugs other than controlled substances and operates as a labeling requirement for blister-packaged pharmaceuticals. The measure is narrow in scope and focused on packaging identification rather than drug approval, prescribing, or dispensing rules. It would add a new section to the Public Health Code, creating a specific labeling standard for manufacturers distributing blister-packaged medications in Michigan. The practical effect would be to make generic identification more visible on certain medication packaging, potentially aiding consumers, pharmacists, and caregivers in recognizing the drug product.

Impact

HB 4252 would add section 17748g to the Michigan Public Health Code, creating a new statutory labeling requirement for manufacturers of non-controlled drugs packaged in blister packs for distribution in Michigan. It would affect pharmaceutical manufacturers and repackagers by requiring generic-name labeling on each blister cell or on the backing of the pack, depending on the packaging design. The bill would not change controlled-substance rules, but it would impose a new compliance obligation for certain drug packaging sold in the state.

Sentiment

No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, support, or opposition in the available record. Based on the bill text and caption, the proposal appears administrative and consumer-oriented, with an emphasis on clearer drug identification. The available materials do not show any formal controversy or amendment activity.

Contention

Because there are no transcripts or votes in the provided context, no specific points of contention can be identified from the legislative record. Potential areas of concern, if raised, would likely involve packaging compliance costs for manufacturers, implementation details for blister-pack labeling, and whether the requirement should apply to all packaged drugs or only certain categories. However, these are inferred possibilities rather than documented objections in the available materials.